Analytical Data
-
基因名
IGF-I R
- Application
-
别名
CD221; IGF1-R; IGFIR; JTK13
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P08069
-
表达区间
Tyr763~Leu955
-
分子量
25kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Insulin-like Growth Factor I Receptor (IGF-IR) plays a crucial role in cell growth, differentiation, and survival, making it a key player in various physiological processes and diseases, particularly cancer. The receptor is activated by its ligand, IGF-I, leading to a cascade of signaling pathways that promote cellular proliferation and inhibit apoptosis. In recent years, research has increasingly focused on the role of IGF-IR in tumorigenesis, as its overexpression is often associated with enhanced tumor growth, metastasis, and resistance to therapies. Consequently, IGF-IR presents a promising target for therapeutic interventions, with recombinant proteins engineered to disrupt its function being explored as potential cancer treatments. These recombinant proteins can function as antagonists to block IGF-IR signaling or as monoclonal antibodies designed to inhibit receptor activation and downstream signaling pathways. Additionally, understanding the structure and function of IGF-IR through recombinant protein studies offers insights into its mechanism and interactions, laying the groundwork for developing novel drugs aimed at modulating its activity. Overall, the study of IGF-IR recombinant proteins not only enhances our knowledge of cellular mechanisms underlying various diseases but also contributes to the advancement of targeted therapies in oncology.
